NCT00004376View on ClinicalTrials.gov

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 1994

Study Completion Date

June 30, 2000

Conditions
Tourette Syndrome
Interventions
DRUG

guanfacine

All Listed Sponsors
collaborator

Yale University

OTHER

lead

National Center for Research Resources (NCRR)

NIH

NCT00004376 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder | Biotech Hunter | Biotech Hunter